Pai M, Furin J. Tuberculosis innovations mean little if they cannot save lives. Elife 2017; 6: e25956.
World Health Organization. Global Tuberculosis Report 2018. URL: http://www.who.int/tb/publications/global_report/en/ (accessed 2 Dec 2018). Geneva: WHO, 2017.
Mwangwa F, Chamie G, Kwarisiima D, et al. Gaps in the Child Tuberculosis Care Cascade in 32 Rural Communities in Uganda and Kenya. J Clin Tuberc Other Mycobact Dis 2017; 9: 24–29.
Pai M, Correa N, Mistry N, Jha P. Reducing global tuberculosis deathstime for India to step up. Lancet 2017; 389(10075): 1174–1176.
Cazabon D, Alsdurf H, Satyanarayana S, et al. Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2017; 56: 111–116.
Cazabon D, Suresh A, Oghor C, et al. Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?. Eur Resp Journal 2017; 50: 1700918.
Detjen AK, DiNardo AR, Leyden J, et al. Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in children: a systematic review and metaanalysis. Lancet Respir Med 2015; 3(6): 451–461.
Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med 2006; 173(10): 1078–1090.
Szkwarko D, Hirsch-Moverman Y, Du Plessis L, Du Preez K, Carr C, Mandalakas AM. Child contact management in high tuberculosis burden countries: A mixed-methods systematic review. PLoS One 2017; 12(8): e0182185.
Nachman S, Ahmed A, Amanullah F, et al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis 2015; 15(6): 711–720.
United Nations General Assembly. Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. URL: http://www.un.org/en/ga/search/view_doc.asp?symbol=A/RES/73/3 (accessed 29 Oct 2018)2018. (accessed.
World Health Organization. Best practices in child and adolescent tuberculosis. URL: http://apps.who.int/iris/bitstream/handle/10665/274373/9789241514651-eng.pdf?ua=1 (accessed 5 Jan 2019). 2018.
Raizada N, Khaparde SD, Salhotra VS, et al. Accelerating access to quality TB care for pediatric TB cases through better diagnostic strategy in four major cities of India. PLoS One 2018; 13(2): e0193194.
Raizada N, Sachdeva KS, Nair SA, et al. Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB. PLoS One 2014; 9(8): e105346.
Raizada N, Khaparde SD, Rao R, et al. Upfront Xpert MTB/RIF testing on various specimen types for presumptive infant TB cases for early and appropriate treatment initiation. PLoS One 2018; 13(8): e0202085.
McDowell A, Raizada N, Khaparde SD, et al. “Before Xpert I only had my expertise”: A qualitative study on the utilization and effects of Xpert technology among pediatricians in 4 Indian cities. PLoS One 2018; 13(3): e0193656.
World Health Organization. Fixed-dose combinations for the treatment of TB in children. https://www.who.int/tb/FDC_Factsheet.pdf?ua=1 (accessed 5 Jan 2019). 2018.
World Health Organization. WHO treatment guidelines for multidrugand rifampicin-resistant tuberculosis. 2018 update. URL: https://www.who.int/tb/publications/2018/WHO.2018.MDR-TB.Rx.Guidelines.prefinal.text.pdf (accessed 5 Jan 2019). 2018.
Diallo T, Adjobimey M, Ruslami R, et al. Safety and Side Effects of Rifampin versus Isoniazid in Children. The New England journal of medicine 2018; 379(5): 454–463.
Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review. Int J Tuberc Lung Dis 2018; 22(12): 1422–1428.
